QJQiwei Jiang

Qiwei Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qiwei Jiang has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Palmitoylation of Smad2 assists TGFβ-Smad signaling to promote breast cancer metastasis

    by Yi Zhang, Tiantian Yu, Lei Wang, Wei Xie, Jianting Long, Qiwei Jiang, Jianping Guo

    Although the role of palmitic acid (PA) as a membrane component in promoting cancer invasion and migration has been explored, it remains unclear whether and how PA enhances breast cancer metastasis via palmitoylation modification. Here, we observed that PA promotes epithelial-mesenchymal transition (EMT), invasion, and migration in breast cancer cells, which could be antagonized by the palmitoyl-transferase inhibitor 2-bromopalmitate (2-BP) through regulating TGFβ-Smad pathway. Specifically, we screened and identified that Smad2 undergoes ZDHHC7-mediated palmitoylation, which stabilizes Smad2 protein, enhances Smad2/Smad3 interaction, and promotes their binding to DNA elements following TGFβ stimulation, thereby promoting EMT. Consequently, ZDHHC7 enhanced breast cancer cell migration, and its depletion effectively suppressed breast cancer lung metastasis. Based on these findings, we generated cell-penetrating peptides to block Smad2 palmitoylation, resulting in disrupting its interaction with Smad3, and in turn attenuate breast cancer EMT, invasion, and migration in cells and in orthotopic mouse models. In summary, our study reveals a novel mechanism by which PA promotes breast cancer metastasis through ZDHHC7-mediated palmitoylation of Smad2, and proposes a therapeutic strategy to inhibit breast cancer lung metastasis by using a specific peptide targeting this modification.

  • Open Access

    IKBKE-YAP axis-mediated reciprocal inhibition between Hippo and NF-κB pathways complementarily drives liver tumorigenesis

    by Xi Yu, Bing Gao, Wei Chen, Xueji Wu, Zimin Song, Lei Wang, Qiwei Jiang, Shunli Shen, Wei Xie, Jianping Guo

    Inactivation of the Hippo signaling pathway critically contributes to hepatocellular carcinoma (HCC) tumorigenesis. However, directly targeting YAP, the key downstream effector of this pathway, has yielded limited clinical benefit in HCC. Here, we report that, in response to inflammatory stimuli, besides promoting inflammation, IKBKE inactivates YAP in liver cancer cells through direct interaction. Consequently, inhibition of IKBKE leads to elevated YAP transcriptional activity, which in turn confers resistance to IKBKE blockade. Mechanistically, IKBKE directly phosphorylates YAP, thereby blocking its nuclear translocation and promoting its degradation. As a result, IKBKE depletion sensitizes HCC cells to YAP inhibitors. Conversely, YAP blockade elevates NF-κB signaling via transcriptional induction of IKBKE , contributing to chemoresistance. Notably, combined inhibition of YAP and IKBKE synergistically suppresses tumor growth in both xenograft and C-Myc -driven HCC mouse models. Collectively, we report a bidirectional negative feedback loop between the Hippo and NF-κB pathways in liver cancer, orchestrated by the reciprocal interplay between YAP and IKBKE. This regulatory circuit supports a rational dual-drug strategy combining IKBKE inhibitors with YAP blockade for effective HCC interventions.

  • Open Access

    Supplementary Data from AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis

    by Zicheng Sun, Qiwei Jiang, Bing Gao, Xiaomei Zhang, Lang Bu, Lei Wang, Ying Lin, Wei Xie, Jie Li, Jianping Guo

    Including supplementary figure S1-9

  • TRIM21 and OTUD6A orchestrate AKT K27-linked atypical ubiquitination to modulate cancer chemoresistance

    by Qiwei Jiang, Peipei Song, Shuishen Zhang, Qin Ren, Meiyan Zhu, Jiawei Ge, Lang Bu, Wei Chen, Xueji Wu, Shiyao Han, et al.

    Ubiquitination regulates various physiological and pathological processes. However, the impact of atypical AKT ubiquitination and its potential role in tumorigenesis remain unclear. Here we show that AKT is modified by K27-linked ubiquitination by the E3 ubiquitin ligase TRIM21, a process antagonized by the deubiquitinase OTUD6A. As such, TRIM21 acts as a tumor suppressor by repressing AKT activity, whereas OTUD6A counteracts AKT suppression. Mechanistically, TRIM21-mediated AKT ubiquitination disrupts SKP2-mediated or TRAF6-mediated K63 ubiquitination, thereby blocking AKT membrane localization and its kinase activity. Upon activation in response to amino acids, S6K1 directly phosphorylates and inactivates OTUD6A, enabling a negative feedback loop regulating AKT activity in a deubiquitination-dependent manner. In agreement with this model, Otud6a deficiency reduces lung tumorigenesis in a KrasG12D-driven lung cancer mouse model and TRIM21 induction alleviates hyperactive AKT-induced tumor growth in vivo. Thus, our findings unveil a fine-tuned regulation of AKT through atypical ubiquitination and suggest the strategy for combating AKT-driven cancers by targeting the TRIM21–OTUD6A axis.


  • Open Access

    Supplementary Data from AKT blocks SIK1-mediated repression of STAT3 to promote breast tumorigenesis

    by Zhicheng Sun, Qiwei Jiang, Bing Gao, Xiaomei Zhang, Lang Bu, Lei Wang, Ying Lin, Wei Xie, Jie Li, Jianping Guo

    Including supplementary figure S1-9

  • Open Access

    Supplementary Data from AKT blocks SIK1-mediated repression of STAT3 to promote breast tumorigenesis

    by Zhicheng Sun, Qiwei Jiang, Bing Gao, Xiaomei Zhang, Lang Bu, Lei Wang, Ying Lin, Wei Xie, Jie Li, Jianping Guo

    Including supplementary figure S1-9

  • Open Access

    Data from AKT blocks SIK1-mediated repression of STAT3 to promote breast tumorigenesis

    by Zhicheng Sun, Qiwei Jiang, Bing Gao, Xiaomei Zhang, Lang Bu, Lei Wang, Ying Lin, Wei Xie, Jie Li, Jianping Guo

    The PI3K-AKT signaling pathway is frequently dysregulated in cancer, and it is hyperactivated in approximately 50% of breast cancers. While inhibitors directly targeting the PI3K-AKT axis have been developed, clinical efficacy has been limited to only a subset of patients. Identification of mechanisms underlying AKT-driven tumorigenesis could lead to alternative approaches to block pathway signaling and suppress breast tumor growth. Mass spectrometry-based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds AKT and undergoes AKT-mediated phosphorylation, which compromises SIK1 tumor-suppressive functions. As a result, AKT relieved the binding and repression of STAT3 by SIK1 in a phosphorylation-dependent manner, resulting in breast cell tumorigenesis. Following AKT-mediated phosphorylation, SIK1 interacted with 14-3-3 and was translocated to the cytoplasm where the isomerase Pin1 facilitated SIK1 interaction with the E3 ligase ITCH to promote SIK1 ubiquitination and subsequent degradation. These findings indicate that SIK1 is a substrate of AKT that links AKT oncogenic function to STAT3 activation, highlighting targeting of the JAK2-STAT3 axis as a strategy to treat AKT-driven breast cancer.

  • Open Access

    Atypical inflammatory kinase IKBKE phosphorylates and inactivates FoxA1 to promote liver tumorigenesis

    by Bing Gao, Xueji Wu, Lang Bu, Qiwei Jiang, Lei Wang, Haining Liu, Xiaomei Zhang, Yuanzhong Wu, Xiaoxing Li, Jingting Li, et al.

    Physiologically, FoxA1 plays a key role in liver differentiation and development, and pathologically exhibits an oncogenic role in prostate and breast cancers. However, its role and upstream regulation in liver tumorigenesis remain unclear. Here, we demonstrate that FoxA1 acts as a tumor suppressor in liver cancer. Using a CRISPR-based kinome screening approach, noncanonical inflammatory kinase IKBKE has been identified to inhibit FoxA1 transcriptional activity. Notably, IKBKE directly binds to and phosphorylates FoxA1 to reduce its complex formation and DNA interaction, leading to elevated hepatocellular malignancies. Nonphosphorylated mimic Foxa1 knock-in mice markedly delay liver tumorigenesis in hydrodynamic transfection murine models, while phospho-mimic Foxa1 knock-in phenocopy Foxa1 knockout mice to exhibit developmental defects and liver inflammation. Notably, Ikbke knockout delays diethylnitrosamine (DEN)-induced mouse liver tumor development. Together, our findings not only reveal FoxA1 as a bona fide substrate and negative nuclear effector of IKBKE in hepatocellular carcinioma (HCC) but also provide a promising strategy to target IKBEK for HCC therapy.


  • Open Access

    Supplementary Data from AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis

    by Zicheng Sun, Qiwei Jiang, Bing Gao, Xiaomei Zhang, Lang Bu, Lei Wang, Ying Lin, Wei Xie, Jie Li, Jianping Guo

    Including supplementary figure S1-9

  • Open Access

    Data from AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis

    by Zicheng Sun, Qiwei Jiang, Bing Gao, Xiaomei Zhang, Lang Bu, Lei Wang, Ying Lin, Wei Xie, Jie Li, Jianping Guo

    The PI3K–AKT signaling pathway is frequently dysregulated in cancer, and it is hyperactivated in approximately 50% of breast cancers. Although inhibitors directly targeting the PI3K–AKT axis have been developed, clinical efficacy has been limited to only a subset of patients. Identification of mechanisms underlying AKT-driven tumorigenesis could lead to alternative approaches to block pathway signaling and suppress breast tumor growth. Mass spectrometry–based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds AKT and undergoes AKT-mediated phosphorylation, which compromises SIK1 tumor-suppressive functions. As a result, AKT relieved the binding and repression of STAT3 by SIK1 in a phosphorylation-dependent manner, resulting in breast cell tumorigenesis. Following AKT-mediated phosphorylation, SIK1 interacted with 14-3-3 and was translocated to the cytoplasm where the isomerase Pin1 facilitated SIK1 interaction with the E3 ligase ITCH to promote SIK1 ubiquitination and subsequent degradation. These findings indicate that SIK1 is a substrate of AKT that links AKT oncogenic function to STAT3 activation, highlighting targeting of the JAK2–STAT3 axis as a strategy to treat AKT-driven breast cancer.Significance:AKT binds and phosphorylates SIK1 to overcome SIK1-mediated repression of STAT3, indicating that STAT3 is a potential therapeutic target in breast cancer with hyperactive AKT signaling.